Avagacestat is a recently developed arylsulfonamide γ-secretase inhibitor with high selectivity for APP over Notch, which successfully reduces CSF Aβ levels in the animal models without any Notch-related toxicity.314 Avagacestat was considered as a promising AD treatment with the ability to selectively inhibit the APP processing without affecting the Notch pathway. The gene discussed is APP; the disease is Alzheimer disease.